General Information

Registration, Students and Bursaries

Discounted rates are offered to RSC, DMDG and BPS members. To join any of these bodies, please visit the website below. Some student bursaries are available.

	to 18th December	from 19th December
RSC, DMDG or BPS member	£180	£270
Non-member	£250	£375
RSC, DMDG or BPS student* member	£80	£120
Student* non-member	£100	£150
Exhibition stand space with one full delegate	£500	
Conference dinner on 8th February	£50	

* Student is undergraduate or post-graduate, not post-doc.

Sponsorship and Exhibition Opportunities

Sponsorship and exhibition opportunities are available for this meeting. Please contact the secretariat for further details.

Conference Dinner

The conference dinner will be held on the evening of Monday, 8th February. This is an optional extra, charged at £50. Additional information will be provided shortly.

Venue

Royal Society of Chemistry at Burlington House, Piccadilly, London, W1J

Organising Committee

Steve Alexander, BPS and University of Nottingham
Toby Athersuch, Imperial College London
Talja Dempster, BPS
Peter Kilford, DMDG and Covance
Graeme Scarfe, DMDG and AstraZeneca
Susanne Schweda, BPS
Andrew Stachulski, RSC and University of Liverpool
Ian Wilson, DMG and Imperial College London



Secretariat Contact

Maggi Churchouse, 3 East Barn, Market Weston Road, Thelnetham, Diss IP22 1JJ, UK
telephone and fax +44 (0)1359 221004, maggi@maggichurchouseevents.co.uk

Website: www.maggichurchouseevents.co.uk/bmcs

Second Announcement and Call for Posters



3rd New Perspectives in DMPK: the impact of drug design

Royal Society of Chemistry at Burlington House, London, UK

Monday - Tuesday, 8th - 9th February 2016

Organised jointly by the RSC Biological and Medicinal Chemistry Sector, the British Pharmacological Society, the Drug Metabolism Group, and the Drug Metabolism Discussion Group

ROYAL SOCIETY OF CHEMISTRY | BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR

DRUG METABOLISM discussion group

BRITISH PHARMACOLOGICAL SOCIETY

Synopsis

This meeting will provide a forum for the exchange of ideas between principal members of the DMPK research community. Keynote talks from industry leaders will provide global perspectives on how
DMPK can bring value to the process on informing drug discovery. The emphasis will be on building dialogue between participants who will range from experienced project/laboratory

Who should attend?

Medicinal chemists, drug discovery scientists, pharmacologists, toxicologists - from academia and industry.

Programme

Monday, 8th February

12:00 Registration and lunch

13:00 *Welcome*
Peter Kilford, Covance, UK
Joint Organising Committee (RSC-BMCS, DMDG, BPS, DMG)

13:10 **Keynote presentation**: *Evolution of DMPK and drug design*
Charlotte Allerton, Pfizer, US

Session 1: Flash poster presentations
Session chair: **Toby Athersuch**, Imperial College London / DMG

14:00 10 x 2-minute single-slide presentations

Session 2: Understanding and exploiting endogenous drug targets (I)
Session chair: **Steve Alexander**, University of Nottingham / BPS

14:40 *Facilitated uptake of CNS drugs and drug candidates across the BBB*
Scott Summerfield, GlaxoSmithKline, UK

15:20 *Application of a deuterium replacement strategy to modulate the pharmacokinetics of a novel CRF1 antagonist*
Rowan Stringer, Novartis, Switzerland

16:00 Refreshments

Session 3: Understanding and exploiting endogenous drug targets (II - oncology)
Session chair: **Graeme Scarfe**, AstraZeneca / DMDG

16:40 *CYP1A1, 1B1 and CYP2W1 as cancer targets for duocarmycin bioprecursor development*
Klaus Pors, University of Bradford, UK

17:20 *Irreversible covalent inhibition - modelling and modulating compound reactivity and its exploitation against EGFR mutant kinase*
Nicola Colclough, AstraZeneca, UK

18:00 Drinks reception
19:00 Conference dinner (optional)
22:30 Close

Programme (continued)

Tuesday, 9th February

Session 4 Physiochemical aspects of DMPK
Session chair: **Andrew Stachulski**, University of Liverpool / RSC-BMCS

09:00 *Chemical reactivity in drug design - the good, the bad and the ugly*
Philip MacFaul, RedX Pharma, UK

09:40 *Piloting the progression of reactive metabolites through drug discovery*
Richard Schneider, Pfizer Worldwide R&D, USA

10:20 Refreshments

Session 5: From simulation to reality (I - modelling complexity)
Session chair: **Toby Athersuch**, Imperial College London / DMG

10:40 *Computational predictive ADMET: guiding medicinal chemistry*
Neil Berry, University of Liverpool, UK

11:20 In silico *models in lead optimization*
Cornelis Hop, Genentech, USA

12:00 *Why DMPK influence is more important than ever*
Richard Weaver, XenoGesis, UK

12:40 Lunch and poster session



Session 6: From simulation to reality (II - *in silico* findings to practical applications)
Session chair: **Peter Kilford**, Covance / DMDG

14:00 *Investigating and predicting how metabolism changes molecules and their properties*
Robert Glen, Imperial College London and University of Cambridge, UK

14:40 *PBPK, PKPD model based approaches to support drug design for different modalities*
Thierry Lavé, Roche, Switzerland

15:20 *PKPD understanding to define the PK profile for the intended dose / schedule*
Owen Jones, AstraZeneca, UK

16:00 Concluding remarks

Call for Posters

The call for posters is now open, and abstracts are invited for posters. The closing date is 15th January, and a template should be downloaded from the website, www.maggichurchouseevents.co.uk/bmcs.

Some presenters will be selected to deliver a two-minute flash oral presentation. Please indicate whether you wish to be considered for this.

ROYAL SOCIETY OF CHEMISTRY | BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR

DRUG METABOLISM discussion group

BRITISH PHARMACOLOGICAL SOCIETY